Join us on Tuesday, January 19^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from Bristol-Myers Squibb Company, Jazz Pharmaceuticals Inc, Merck, Novocure Inc, and Regeneron Pharmaceuticals Inc and Sanofi Genzyme.

Tuesday, January 19, 2021
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

MODULE 1: Current and Future Therapeutic Strategies for Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation

• Biologic and clinical factors in the selection of first-line therapy for patients with metastatic NSCLC without a targetable tumor mutation; roles of PD-L1 expression and tumor mutational burden in decision-making
• Clinical trial database supporting the FDA approvals of pembrolizumab and atezolizumab administered as monotherapy and combined with chemotherapy as first-line treatment for metastatic NSCLC
• Current clinical role of atezolizumab in combination with carboplatin/paclitaxel/bevacizumab as first-line therapy for patients with metastatic nonsquamous NSCLC
• Design, eligibility criteria and key efficacy and safety findings from the Phase III CheckMate 227 and CheckMate 9LA trials evaluating up-front nivolumab/ipilimumab with and without chemotherapy for metastatic NSCLC
• Recent FDA approvals of first-line nivolumab/ipilimumab with and without chemotherapy; patient selection and optimal integration into practice
• Emerging safety and efficacy data from the Phase III POSEIDON trial comparing durvalumab or durvalumab/tremelimumab in combination with platinum-based chemotherapy to chemotherapy alone as first-line therapy
• Other immunotherapeutic targets in metastatic NSCLC; results from the Phase II CITYSCAPE trial evaluating the addition of the novel anti-TIGIT antibody tiragolumab to atezolizumab as first-line therapy
• Management of disease that has progressed on anti-PD-1/PD-L1-based therapy in the first-line setting; current role of approved agents and regimens (eg, ramucirumab, afatinib, bevacizumab)

MODULE 2: Evidence-Based Management of Locally Advanced NSCLC, Small Cell Lung Cancer (SCLC) and Mesothelioma

• Long-term efficacy and safety findings from the Phase III PACIFIC trial evaluating consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC
• Outcomes with durvalumab in various subgroups in the PACIFIC trial; patient selection for and practical implementation of sequential durvalumab
• Other ongoing and planned clinical trials of immune checkpoint inhibitors for patients with nonmetastatic NSCLC
• Design, eligibility criteria and key efficacy and safety findings from the pivotal Phase III IMpower133 and CASPIAN trials evaluating atezolizumab or durvalumab, respectively, in combination with chemotherapy for patients with previously untreated extensive-stage SCLC
• Appropriate integration of carboplatin/etoposide/atezolizumab and platinum/etoposide/durvalumab into the current management of extensive-stage SCLC
• Available data, ongoing evaluation and current clinical role of anti-PD-1/PD-L1 antibodies alone or in combination with anti-CTLA-4 antibodies for SCLC
• Design, eligibility criteria and primary and secondary endpoints achieved in the Phase II basket trial assessing lurbinectedin monotherapy for patients with SCLC and disease progression after prior platinum-based therapy
• Recent FDA approval of lurbinectedin for patients with progressive SCLC; optimal integration into practice and ongoing investigation
• Design, entry criteria and emerging efficacy findings from the Phase III CheckMate 743 trial comparing nivolumab/ipilimumab to platinum-based chemotherapy for previously untreated malignant pleural mesothelioma (MPM); implications for clinical care and future research
• Mechanism of action of tumor treating fields (TTFields) and biologic rationale for their investigation in MPM
• Key efficacy and safety outcomes from the Phase II STELLAR trial assessing the combination of TTFields with systemic chemotherapy as first-line treatment for unresectable MPM; FDA approval and practical incorporation of TTFields into MPM management

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for metastatic non-small cell lung cancer (NSCLC), and discern how these approaches can be optimally employed in patient care.
• Recognize the recent FDA approvals of nivolumab in combination with ipilimumab with and without chemotherapy as first-line treatment for patients with metastatic NSCLC, and appropriately incorporate these novel regimens into current treatment algorithms.
• Consider performance status, prior therapeutic exposure, disease-free interval and other patient- or disease-related factors in the selection of systemic therapy for patients with metastatic NSCLC who experience disease progression on first-line treatment.
• Appraise the FDA approval of anti-PD-L1 antibody consolidation for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be safely integrated into routine clinical practice.
• Assess the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for patients with localized or locally advanced NSCLC, and counsel appropriate patients about availability and participation.
• Evaluate the recent FDA approvals of atezolizumab or durvalumab in combination with platinum-based chemotherapy as first-line therapy for patients with extensive-stage small cell lung cancer (SCLC), and consider how these regimens can be appropriately and safely integrated into clinical practice.
• Develop an understanding of the mechanism of action of lurbinectedin and available clinical trial findings with that agent for patients with SCLC who have experienced disease progression on platinum-containing therapy, and optimally incorporate this FDA-approved strategy into management algorithms.
• Analyze the biologic basis for the investigation of immune checkpoint inhibitors for malignant pleural mesothelioma (MPM), and evaluate emerging Phase III data with and the potential clinical role of nivolumab in combination with ipilimumab for patients with previously untreated disease.
• Recall available efficacy and safety data with the use of tumor treating fields (TTFs) in combination with chemotherapy as first-line therapy for patients with unresectable, locally advanced or metastatic MPM in order to make an informed decision regarding the incorporation of this treatment modality into clinical practice.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Gubens — Advisory Committee: AstraZeneca Pharmaceuticals LP, BeyondSpring Inc, Bristol-Myers Squibb Company, Inivata; Contracted Research: Celgene Corporation, Merck, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc. Dr Ramalingam — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck, Takeda Oncology; Contracted Research: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Takeda Oncology, Tesaro, A GSK Company.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Jazz Pharmaceuticals Inc, Merck, Novocure Inc, and Regeneron Pharmaceuticals Inc and Sanofi Genzyme.